Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The study is designed to see if once daily oral dosing of LY2608204 will help control diabetes as measured by the glycosylated fraction of hemoglobin A (HbA1c) level. It will also help to determine the safety of the medication and the most useful doses of the medication.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Clinical diagnosis of type 2 diabetes mellitus prior to entering the trial
May be treated with:
Must have an Hemoglobin A1c value between 7% and 10%
Must have a body mass index (BMI) between 20 and 40 kg/m2
Must have stable weight during the 3 months prior to Screening (weight change not to exceed 5 kg (11 lb))
If female, you must not be able to get pregnant
Must be well motivated, capable, and willing to complete study required glucose monitoring and instruction
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
240 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal